tirzepatide

FDA Drug Profile — Zepbound, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound KwikPen

tirzepatide is listed in the FDA National Drug Code directory with 141 NDC codes, marketed under brand names including Zepbound, Mounjaro, Mounjaro KwikPen. Available dosage forms: injection, solution, powder.

Drug details

Generic Name
tirzepatide
Brand Names
Zepbound, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound KwikPen, MOUNJARO
Application Number
NDA217806
Sponsor
Eli Lilly And Company
NDC Codes
141
Dosage Forms
INJECTION, SOLUTION, POWDER
Routes
SUBCUTANEOUS
Active Ingredients
TIRZEPATIDE

Indications and Usage

1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.